



Managing Complexity. Enabling Results.

PRESS RELEASE

SNBL CLINICAL PHARMACOLOGY CENTER (SNBL-CPC) APPOINTS DAN RUDIN AS MEDICAL DIRECTOR

Baltimore, MD, December 8th, 2011: SNBL-CPC one of the nation's leading CRO dedicated to Phase I&IIa clinical research is pleased to announce new executive medical leadership with the arrival of Dan Rudin, MD as Medical Director.

Dan Rudin, MD has joined SNBL-CPC as Medical Director. Dr. Rudin will be directing the day to day clinical operations, and providing strategic medical input to our sponsors and internal team regarding clinical trial feasibility, design and execution. Dr. Rudin will also be serving as SNBL's primary principle investigator for numerous clinical trials.

Dr. Mohamed Al-Ibrahim President and Chief Medical Officer of SNBL-CPC said "High quality clinical research is a very complex undertaking. Dr. Rudin has a unique skill set that integrates all the elements that cutting edge clinical research demands. Despite these demands his primary focus is the care and safety of the participants who have chosen to join our clinical trials. That's why our organization selected Dr. Rudin for this key position and we all welcome Dan to this important role."

Dr. Rudin joins us from the Charles River Laboratories in Seattle, Washington where he served as a clinical research physician and principle investigator. In addition, he was also a Clinical Pharmacology Fellow at the prestigious Mayo Clinic where he lead numerous translational programs and taught protocol development and pharmacology. Dr. Rudin also has extensive internal medicine experience in private practice and at the university hospital setting. Dr. Rudin underwent his undergraduate and medical training at Hebrew University Medical School in Jerusalem, Israel.

About SNBL Clinical Pharmacology Center

SNBL-CPC is a 96 bed full service Clinical Pharmacology Research facility based in Baltimore, Maryland. Our team is focused on performing high complexity early phase clinical research programs. We conduct clinical trials for multiple segments of clients, including, pharmaceutical, biotech, academic, and government. In addition, SNBL-CPC offers all ancillary trial support services such as protocol consulting and design, data management, etc. for early phase I-IIa studies. SNBL's focus is on First In-Human, Dose Escalation, SAD, MAD, Food Effect, Novel Delivery, Adaptive design, and Infectious Disease challenge studies sets us apart from the vast majority of Early Phase inpatient clinical research facilities. SNBL-CPC is pleased to offer our new, state of the art clinical safety laboratory that performs all of the standard safety analyses and moderate to high complexity test procedures.

For further information about SNBL-CPC or having our team manage your early phase clinical development program, please contact our client service team at bd@snbl-cpc.com or visit our website at www.snbl-cpc.com.

Contacts:

SNBL-CPC
Felipe Troncoso
+1 (410) 706 8894
ftroncoso@snbl-cpc.com